Tag

Wegovy

All articles tagged with #wegovy

health8 days ago•26 min saved

Neuroscientist warns rapid GLP-1 weight loss may force brain to consume its own tissue

Dr. Tommy Wood, a University of Washington neuroscientist, warns that rapid weight loss from GLP-1 medications like Ozempic and Wegovy can deprive the brain of essential energy. He explains that extreme caloric deficits may force the brain to consume its own white matter, similar to what happens during intense marathon running. While these drugs can improve cognitive health by lowering blood pressure and blood sugar in obese patients, severe under-eating risks long-term cognitive impairment. Wood advises pairing these medications with resistance training and ensuring adequate intake of neuro-nutrients like omega-3s, iron, and B vitamins to protect brain function.

via New York Post|

#brain-health #glp-1-drugs #health

health9 days ago•4 min saved

Neuroscientist warns GLP-1 weight loss drugs may starve brain of vital nutrients

Dr. Tommy Wood, a University of Washington neuroscientist, warns that rapid weight loss from GLP-1 drugs like Ozempic and Wegovy can deprive the brain of essential energy and nutrients. He explains that extreme caloric restriction may force the brain to consume its own tissue, while chronic under-eating reduces critical nutrients like iron, protein, and omega-3 fats. Wood advises pairing these medications with resistance training and ensuring adequate intake of neuro-nutrients to protect cognitive function.

via Fox News|

#brain-health #glp-1-drugs #health

health-and-science9 days ago•3 min saved

Novo Nordisk data shows Wegovy pill sustains weight loss after injection switch

Novo Nordisk presented real-world data indicating that patients switching from injectable obesity drugs to the new oral Wegovy pill continued losing weight. The analysis suggests the pill may offer convenience without sacrificing efficacy, potentially shifting patient preference away from weekly injections.

via CNBC|

#cagrisema #glp-1-drugs #health-and-science

health14 days ago•25 min saved

GLP-1 Weight-Loss Drugs May Lower Cancer Recurrence by Boosting Immune Response, Expert Says

The American Association for Cancer Research's 2026 report notes that obesity is a major cancer risk factor, prompting interest in whether GLP-1 drugs like Ozempic and Mounjaro can reduce cancer incidence. While retrospective studies suggest lower cancer risk and higher survival rates for GLP-1 users, evidence remains mixed, with some studies showing increased risks for specific cancers like thyroid cancer. Dr. Sai Yendamuri of Roswell Park Comprehensive Cancer Center suggests these drugs may alter the body's immune response to fight cancer cells, potentially lowering recurrence rates in lung cancer and melanoma. However, randomized clinical trials are lacking, and it remains unclear if benefits stem from weight loss or direct immune effects. Future trials will determine if GLP-1s can serve as a preventive mechanism for cancer.

via New York Post|

#cancer-research #glp-1-drugs #health

health16 days ago•0 min saved

GLP-1 Makers Face Hundreds of Lawsuits Over Rare Vision Loss

Hundreds of lawsuits have been filed against Novo Nordisk and Eli Lilly, alleging that GLP-1 drugs like Ozempic and Wegovy cause rare, permanent vision loss. The condition, known as NAION, is not listed on U.S. drug labels, though some countries have added warnings. While the FDA investigates the link, drugmakers deny causation, citing mixed research and the condition's low overall risk.

via WESH|

#glp-1-drugs #health #lawsuits

health-and-science17 days ago•6 min saved

GLP-1 Makers Face Surge in Vision Loss Lawsuits as NAION Link Debated

Hundreds of lawsuits allege that popular weight-loss drugs like Ozempic and Wegovy cause rare, permanent vision loss known as NAION. While manufacturers deny causation, citing mixed research, some countries have updated drug labels to include the risk, and the FDA is reviewing the evidence.

via Fox News|

#glp-1-drugs #health-and-science #lawsuits

health17 days ago•249 min saved

GLP-1 Vision Lawsuits Surge as Patients Report Sudden Blindness

Hundreds of lawsuits allege that GLP-1 weight-loss and diabetes drugs like Wegovy and Ozempic caused rare vision loss. A 66-year-old patient describes sudden blindness in one eye. Drugmakers deny causation, while experts note the risk is extremely low but potentially real.

via TODAY.com|

#glp-1-drugs #health #lawsuits

health17 days ago•3 min saved

Lawsuits Accuse GLP-1 Weight-Loss Drugs of Rare Vision Loss

Dozens of U.S. plaintiffs allege GLP-1 drugs such as Ozempic, Wegovy and Mounjaro cause nonarteritic anterior ischemic optic neuropathy (NAION), a rare, potentially permanent loss of vision. The suits claim warnings were inadequate, with cases arising within 6–18 months of starting treatment. Novo Nordisk and Eli Lilly are contesting the claims, while regulators report mixed evidence and emphasize the overall low risk, even as the GLP-1 market faces scrutiny and potential impact from litigation.

via aljazeera.com|

#glp-1 #health #lawsuits

business17 days ago•2 min saved

Novo Nordisk Eyes M&A to Diversify Beyond GLP-1 Amid Weight-Loss Push

Novo Nordisk signaled it may pursue acquisitions to close gaps against rivals in the crowded weight‑loss market, as investors reacted skeptically to a Capital Markets Day plan. CEO Mike Doustdar said the firm aims to diversify beyond diabetes and obesity into adjacent areas and could strike deals outside its core as Wegovy’s exclusivity wanes, with a long‑range plan to launch five multi‑blockbuster drugs by 2030 and target more than 150 billion Danish kroner in sales by 2035; the stock has faced pressure amid the broader competitive landscape, including Lilly’s dominance in GLP-1 therapies.

via cnbc.com|

#business #diversification #glp-1

business18 days ago•7 min saved

Novo bets on Consumer Rx and five-blockbuster lineup amid investor pushback

At a London Capital Markets Day, Novo Nordisk outlined a Consumer Rx strategy and a plan to launch at least five multi-blockbusters by 2030, led by CagriSema (cagrilintide plus semaglutide) with assets like denecimig and zenagamtide; the push includes expanding Wegovy, broadening U.S. access, and boosting manufacturing, while cutting roughly 4,000 more jobs; investors sent the stock lower as they pressed for more detail on M&A and execution risk.

via Fierce Pharma|

#business #cagrisema #consumer-rx

finance18 days ago•20 min saved

Novo Nordisk slides on patent cliff worries after cautious growth targets

Novo Nordisk shares fell more than 7% after its Capital Markets Day failed to reassure investors about weight‑loss drug competition and looming semaglutide patent expiry, as the company projects five multi‑blockbuster drugs by 2030 and over 150 billion Danish kroner in risk‑adjusted pipeline sales by 2035, while acknowledging a CagriSema Phase 3 miss and tight competition in the obesity drug market (Lilly leads ~61% vs Novo's ~39%).

via Yahoo Finance|

#finance #novo-nordisk #obesity-drugs

business25 days ago•2 min saved

Novo Nordisk pivots to 'Novo' branding to regain momentum

Novo Nordisk unveiled a sweeping rebrand to use 'Novo' as its everyday name, with a new right-facing logo and a cultural framework called 'The Novo Way' and 'Lasting Health Starts Now' aimed at making the company more memorable and responsive in the competitive obesity/diabetes space. The move comes as Novo contends with Eli Lilly’s rapid growth in the same franchise (Zepbound, Mounjaro, Foundayo) and after branding tweaks like retiring the Rybelsus name and positioning the Ozempic pill, in a bid to rebuild momentum and align brand with faster, consumer-driven health engagement.

via Fierce Pharma|

#business #eli-lilly #novo-nordisk

business25 days ago•2 min saved

Novo Nordisk rebrands to Novo, launches cultural overhaul to reclaim obesity-drug lead

Novo Nordisk will rebrand to Novo and overhaul its corporate culture to regain momentum in obesity drugs amid fierce competition from Eli Lilly; the changes include four guiding principles—patient-first innovation, higher performance through clearer priorities and simpler workflows, and an unwavering commitment to safety and ethics—and will be outlined at the Sept. 21 Capital Markets Day under the banner 'Lasting Health Starts Now.' The legal name remains Novo Nordisk, and Wegovy’s oral version provides a tailwind despite Novo’s lag in market share.

via CNBC|

#business #eli-lilly #novo-nordisk

health1 month ago•13 min saved

Triple-hormone weight-loss jab outpaces Mounjaro in new study

A new study shows retatrutide, an experimental triple-hormone weight‑loss jab, delivering about 22% body-weight loss in roughly 48 weeks—outperforming Mounjaro's ~19% over ~17 months; GLP-1 drugs like Wegovy and Ozempic hover around 18% in similar timeframes, while retatrutide remains unapproved by the MHRA in the UK. The analysis draws on 38 trials with more than 25,000 participants.

via The Independent|

#glp-1 #health #mounjaro

health1 month ago•17 min saved

Wegovy extends mouse lifespan, fueling anti-ageing discussions

A study found the weight‑loss drug Wegovy (semaglutide) extended lifespans by about 12% in healthy‑weight female mice starting at 20 months, with signs of reduced inflammation, DNA damage and cellular senescence, suggesting potential anti‑ageing effects beyond weight loss. Experts caution that results in mice may not translate to humans, noting sex and species differences, possible side effects, and cost; more research is needed before any anti‑ageing use.

via The i Paper|

#ageing #health #longevity